



## Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in *P. falciparum* populations in malaria vectors across Cameroon

Francis N. Nkemngo<sup>a,b,\*</sup>, Leon M.J. Mugenzi<sup>a</sup>, Magellan Tchouakui<sup>a</sup>, Daniel Nguiffo-Nguete<sup>a</sup>, Murielle J. Wondji<sup>a,c</sup>, Bertrand Mbakam<sup>a</sup>, Micareme Tchoupo<sup>a</sup>, Cyrille Ndo<sup>a,d</sup>, Samuel Wanji<sup>b,e</sup>, Charles S. Wondji<sup>a,c,\*</sup>

<sup>a</sup> Centre for Research in Infectious Diseases (CRID), P.O. Box 13591, Yaoundé, Cameroon

<sup>b</sup> Department of Microbiology and Parasitology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon

<sup>c</sup> Vector Biology Department, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, United Kingdom

<sup>d</sup> Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

<sup>e</sup> Research Foundation in Tropical Diseases and Environment, Buea, Cameroon

### ARTICLE INFO

Edited by John Doe

#### Keywords:

Malaria  
*Anopheles* vectors  
*P. falciparum*  
*k13* & *mdr1*  
 Drug resistance  
 Cameroon

### ABSTRACT

**Background:** Monitoring of drug resistance in *Plasmodium* populations is crucial for malaria control. This has primarily been performed in humans and rarely in mosquitoes where parasites genetic recombination occurs. Here, we characterized the *Plasmodium* spp populations in wild *Anopheles* vectors by analyzing the genetic diversity of the *P. falciparum* *kelch13* and *mdr1* gene fragments implicated in artemisinin and partner drug resistance across Cameroon in three major malaria vectors.

**Methods:** *Anopheles* mosquitoes were collected across nine localities in Cameroon and dissected into the head/thorax (H/T) and abdomen (Abd) after species identification. A TaqMan assay was performed to detect *Plasmodium* infection. Fragments of the *Kelch 13* and *mdr1* genes were amplified in *P. falciparum* positive samples and directly sequenced to assess their drug resistance polymorphisms and genetic diversity profile.

**Results:** The study revealed a high *Plasmodium* infection rate in the major *Anopheles* vectors across Cameroon. Notably, *An. funestus* vector recorded the highest sporozoite (8.0%) and oocyst (14.4%) infection rates. A high *P. falciparum* sporozoite rate (80.08%) alongside epidemiological signatures of significant *P. malariae* (15.9%) circulation were recorded in these vectors. Low genetic diversity with six (A578S, R575I, G450R, L663L, G453D, N458D) and eight (H53H, V62L, V77E, N86Y, G102G, L132I, H143H, Y184F) point mutations were observed in the *k13* and *mdr1* backbones respectively. Remarkably, the R575I (4.4%) *k13* and Y184F (64.2%) *mdr1* mutations were the predominant variants in the *P. falciparum* populations.

**Conclusion:** The emerging signal of the R575I polymorphism in the *Pfk13* propeller backbone entails the regular surveillance of molecular markers to inform evidence-based policy decisions. Moreover, the high frequency of the <sup>86</sup>N<sup>184</sup>F allele highlights concerns on the plausible decline in efficacy of artemisinin-combination therapies (ACTs); further implying that parasite genotyping from mosquitoes can provide a more relevant scale for quantifying resistance epidemiology in the field.

**Abbreviations:** ACTs, Artemisinin Combination Therapy; AL, Artemether-Lumefantrine; ASAQ, Amodiaquine-Artesunate; ITNs, Insecticide-Treated Nets; NMCP, National Malaria Control Program; Art-R, Artemisinin Resistance; ELISA, Enzyme-Linked Immunosorbent Assay; HLC, Human Landing Catch; PSC, Pyrethrum Spray Catch; *k13PD*, *Kelch 13* propeller domain; *mdr1*, multi-drug resistance-1; PIR, *Plasmodium* infection rate; P.OVM, *Plasmodium ovale, vivax* and *malariae*; Spz, Sporozoite; WHO, World Health Organization.

\* Corresponding authors at: Centre for Research in Infectious Diseases (CRID), P.O. Box 13591, Yaoundé, Cameroon.

**E-mail addresses:** [francis.nkemngo@crid-cam.net](mailto:francis.nkemngo@crid-cam.net) (F.N. Nkemngo), [leon.mugenzi@crid-cam.net](mailto:leon.mugenzi@crid-cam.net) (L.M.J. Mugenzi), [magellan.tchouakui@crid-cam.net](mailto:magellan.tchouakui@crid-cam.net) (M. Tchouakui), [daniel.nguiffo@crid-cam.net](mailto:daniel.nguiffo@crid-cam.net) (D. Nguiffo-Nguete), [murielle.wondji@lstmed.ac.uk](mailto:murielle.wondji@lstmed.ac.uk) (M.J. Wondji), [bertrand.mbakam@crid-cam.net](mailto:bertrand.mbakam@crid-cam.net) (B. Mbakam), [micareme.tchoupo@crid-cam.net](mailto:micareme.tchoupo@crid-cam.net) (M. Tchoupo), [cyrille.ndo@crid-cam.net](mailto:cyrille.ndo@crid-cam.net) (C. Ndo), [swanji@yahoo.fr](mailto:swanji@yahoo.fr) (S. Wanji), [charles.wondji@lstmed.ac.uk](mailto:charles.wondji@lstmed.ac.uk) (C.S. Wondji).

<https://doi.org/10.1016/j.gene.2022.146339>

Received 28 December 2021; Received in revised form 10 February 2022; Accepted 14 February 2022

Available online 17 February 2022

0378-1119/© 2022 The Authors.

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

The triad biological interaction between *Anopheles* vectors, *Plasmodium* parasites, and humans is responsible for malaria, a disease of global public health priority (WHO, 2021). The disease burden predominates in sub-Saharan Africa with Cameroon accounting for 6,450,000 cases in 2020, mostly affecting children below five years (WHO, 2021; Nkemngo, 2020; Antonio-Nkondjio, 2019). This high score in malaria cases is in part due to the heterogenous vectorial complexity and competence of the major *Anopheles* mosquitoes particularly *An. gambiae*; *An. funestus* and *An. coluzzii* in successfully transmitting the deadliest, most prevalent, most drug-resistant *Plasmodium* species, *P. falciparum* across diverse bio-ecological zones within the country (Antonio-Nkondjio, 2019; Antonio-nkondjio, 2006; The PMI VectorLink Project, A.A., 2020). *P. falciparum* is responsible for about 93% of cases and death with the remaining fraction attributed to non-falciparum species including *P. malariae*, *P. ovale*, and *P. vivax* (hereafter referred to as *P. OVM*) (Tabue, 2019; Fru-Cho, 2014; Akindeh, 2021). In particular, *P. malariae* significantly predominates as co-infection with *P. falciparum* to widen the parasite transmission window and disease severity (Roman, 2018). *Anopheles* mosquito serves both as the vector and the definitive host of the *Plasmodium* parasite and this obligatory co-interaction forms the basis of sporogony (Beier, 1998; Bennink et al., 2016). This stage, usually considered the most important in the parasite life cycle owing to the occurrence of fertilization, genetic exchange, allelic recombination, and sporozoite formation defines the cornerstone of malaria transmission (Paul et al., 2002; Smith and Jacobs-Lorena, 2010). Gametocytes, which comprise 1% (~100–1000) of the parasite biomass (Ngotho, 2019) are the sexual stages involved in the transmission of both drug-resistant and sensitive alleles. In line with this, antimalarial drugs have played a key role in shrinking the parasite population in humans while also preventing mosquitoes from being infected during a blood meal (Peatey, 2012; Drakeley, 2004). In particular, Artemisinin combination therapy (ACT), the first-line treatment against *P. falciparum* infection, has contributed enormously both in decreasing the parasite biomass in humans and reducing transmission capacity (Sawa, 2013; Chotivanich, 2006). Indeed, a modeling study between 2000 and 2015 revealed that 19% of the success in averting malaria burden in endemic countries was attributed to expanded access to ACTs (Bhatt, 2015); diminishing the global malaria mortality curve from 896,000 deaths in 2000 to 627,000 deaths in 2020 (WHO, 2021). However, the emergence of the artemisinin-resistant (AR) *P. falciparum* parasite in Western Cambodia (South East Asia) and recently in Rwanda and Uganda (Africa) threatens to reverse the gains achieved in malaria control over the years (Noedl, 2008; Dondorp, 2009; Uwimana, 2021; Balikagala, 2021; Conrad and Rosenthal, 2019; Fidock and Rosenthal, 2021). Moreover, the widespread molecular resistance to the partner drugs (amodiaquine and mefloquine) is jeopardizing malaria control efforts in the most affected regions (WHO, 2021). This poses an even greater risk to the clinical therapeutic efficacy and sustainability of ACTs particularly in Africa in the absence of newly approved compounds (Ehrlich, 2021; Uwimana, 2021). In order to mitigate the potential risks of Artemisinin and partner drug resistance, molecular markers have been identified to detect resistance at the early stage to improve treatment schemes.

In this regard, the discovery of molecular markers of resistance in the Kelch 13 (*k13*) (Ariey, 2014) and multidrug resistance-1 (*mdr1*) (Duraisingh, 2000) genes through whole-genome sequencing approach and phenotypic studies has facilitated the possibility to monitor and track the emergence and spread of artemisinin and partner drug resistance in real-time and geography. *Plasmodium falciparum* drug resistance monitoring is critical for successful malaria control and elimination (WHO, 2021). Techniques involving genotyping of resistance markers from human blood samples are usually invasive, require huge logistic costs, are time-consuming, and involve a lengthy duration of ethical considerations particularly in malaria-endemic countries (Uwimana, 2021). An alternative cost-effective approach to surveillance of resistant

parasites from human blood in endemic areas is utilizing *Plasmodium*-infected *Anopheles* mosquitoes as a sentinel for the screening of drug resistance genes (Smith-Aguasca, 2019).

Exploiting *Plasmodium*-infected mosquitoes to detect and track resistant parasites in endemic areas through genotyping of molecular markers or assessing signatures of selection through reduced diversity, could provide an early warning signal for the emergence of drug resistance (Smith-Aguasca, 2019; Mharakurwa, 2013). In addition, it will permit the rapid follow-up of the geographical distribution and spread of drug resistance within a country thereby triggering pro-active responses to improve local malaria control strategies (Mharakurwa, 2011).

Therefore, this study aims to firstly establish the prevalence of *Plasmodium* infection in *Anopheles* vectors across nine (09) localities in Cameroon and secondly to characterize the polymorphism profile and genetic variability of *P. falciparum k13* and *mdr1* gene determinants implicated in artemisinin and partner drug resistance in the dominant *Anopheles* mosquitoes circulating across Cameroon.

## 2. Methodology

### 2.1. Study sites

This study was conducted across 09 localities in Cameroon (Fig. 1) representing three major bio-ecological belts mainly equatorial, sudano-guinean, and Sahel regions. The study sites categorized within the tropical equatorial region includes Bankeng (4° 38' 43" N; 12° 13' 03" E) (Elanga-Ndille, 2019), Bonaberi (4° 4' 55.955" N; 9° 39' 53.898" E) (The PMI VectorLink Project, A.A., 2020), Elende (3° 41' 57.27" N, 11° 33' 28.46" E) (Nkemngo, 2020), Elon (N4.23051° E11.60120°) (Elanga-Ndille, 2019), About (3° 7' 0" N, 11° 65' 0" E) (Tchouakui, 2019) and Mangoum (5° 31' N, 10° 37' E) (The PMI VectorLink Project, A.A., 2020). These rural areas (except Bonaberi, an urbanized locality) situated within the forested parts of Cameroon have a high humidity profile characterized by two rainy season shifts, ranging from March to June and September to November. Malaria transmission in this climatic zone is considered stable and perennial. Moreover, the vector dominance of *An. gambiae* s.s in Bankeng and Mangoum; *An. coluzzii* in Bonaberi and *An. funestus* in Elende, Elon, and About pilots the malaria transmission pattern observed in these areas (Nkemngo, 2020; The PMI VectorLink Project, A.A., 2020; Elanga-Ndille, 2019; Elanga-Ndille, 2019). Mibellon (6° 46' N, 11° 70' E) and Gounougou (9° 03' 00" N, 13° 43' 59" E) situated in the sudano-guinean Adamawa region, forms a mid-point between the tropical equatorial south and the savanna north. The climate is characterized by a rainy season from May to September, and a dry season extending from October to April. *An. funestus* and *An. coluzzii* dominate in Mibellon and Gounougou respectively (The PMI VectorLink Project, A.A., 2020; Menze, 2018; Menze, 2016). Simatou (10° 34' N, 14° 30' E) situated in the Sahelian zone is characterized by a short periodic rainy season from May to September and a long dry season from October to April (The PMI VectorLink Project, A.A., 2020). Malaria transmission in this area is seasonal with *An. coluzzii* being the leading vector.

### 2.2. Study design: Mosquito collection across Cameroon

Adult mosquitoes were collected across the 09 localities (Fig. 1) from houses using different collection techniques after ethical approval was obtained from the Cameroon National Committee on Research Ethics for Human Health (N° 2020/05/1234/CE/CNERSH/SP) and verbal consent was sought from village heads and household members. Indoor resting mosquito populations from Elende, Elon, Mibellon, About were collected on the walls and roofs of thatched houses using electrical aspirators (Rule In-Line Blowers, Model 240) (Nkemngo, 2020) while Human Landing Catch (HLC) was employed to capture mosquitoes both inside and outside of homes in the localities of Bonaberi and Gounougou (The PMI VectorLink Project, A.A., 2020). In Bankeng, both indoor aspiration and HLC techniques were utilized for mosquito collection




Fig. 1. A map of the different sampling localities across Cameroon.

while HLC and Pyrethrum Spray Catch (PSC) methods were used for mosquito sampling in Mangoum and Simatou (The PMI VectorLink Project, A.A., 2020). The period of mosquito collection varied across the different study sites: Bankeng (April 2019), Bonaberi (April, August & October 2019), Elende (April to June 2019), Elong (April 2019 & January 2020), Gounougou (April 2019 & June 2020), Mangoum (April 2019 & October 2020), Mibellon (August to September 2019), Obout (May 2016) and Simatou (April 2019, March & June-July 2020). All mosquitoes (F0) were morphologically identified as either *An. gambiae* complex or *An. funestus* group following established protocols (Gillies, 1968; Coetzee, 2020).

Female *Anopheles* mosquito abdomen (Abd) and head/thorax (H/T) were partitioned to discriminate between midgut (Abdomen) and salivary gland (H/T) infection (Foley, 2012). However, this separation technique was not done for mosquito samples from Obout as collected back in 2016. Rather, whole mosquitoes (WM) were used for extraction. All the samples were stored at  $-20^{\circ}\text{C}$  until DNA extraction.

Extraction of genomic DNA from the H/T and Abd of individual dissected female mosquitoes from all the localities (except Obout) was accomplished using the LIVAK method (Livak, K., , 1984). Species identification by PCR was performed to discriminate against *An. funestus* siblings (Koekemoer, 2002) while the SINE-200 method was employed to distinguish members of the *An. gambiae* s.L species complex (Santolamazza, 2008).

### 2.3. TaqMan detection of *Plasmodium* sporozoites and oocysts in field-collected *Anopheles* mosquitoes

Screening for *Plasmodium* infection was done to check for the presence of sporozoite and oocyst using the TaqMan assay (Bass, 2008) for nine localities. The number of samples tested per locality include: Bankeng (n = 287H/T), Bonaberi (n = 262H/T & 372Abd), Elende (n = 1000H/T & 434Abd), Elong (n = 273H/T & 378Abd), Gounougou (n = 465H/T & 558Abd), Mangoum (n = 465Abd), Mibellon (n = 640H/T &

372Abd), Obout (n = 186WM) and Simatou (n = 372H/T and 465Abd). The real-time PCR MX 3005 (Agilent, Santa Clara, CA, USA) system was used for the amplification (Bass, 2008). Briefly, 2  $\mu\text{L}$  of gDNA for each sample was used as template in a 3-step program with a pre-denaturation at  $95^{\circ}\text{C}$  for 10 mins, followed by 40 cycles of 15 sec at  $95^{\circ}\text{C}$  and 1 min at  $60^{\circ}\text{C}$ . The primers (Falcip+: TCT-GAA-TAC-GAA-TGT-C, OVM+: CTG-AAT-ACA-AAT-GCC, Plas-F: GCT-TAG-TTA-CGA-TTA-ATA-GGA-GTAGCT-TG, Plas R: GAA-AAT-CTA-AGA-ATT-TCA-CCTCTG-ACA) were used together with two probes tagged with fluorophores: FAM to detect *Plasmodium falciparum*, and HEX to detect *Plasmodium ovale*, *Plasmodium vivax*, and *Plasmodium malariae*. *P. falciparum* samples and a mix of *P. ovale*, *P. vivax*, and *P. malariae* were used as positive controls. A sub-set of positive samples (for each body part and locality) were subjected to Nested PCR to confirm and discriminate the species detected by TaqMan based on the protocol of (Snounou, 1993) with slight modification using kappa Taq enzyme instead of Dream Taq.

### 2.4. Amplification of *k13* propeller domain and *mdr1* gene fragments of *P. falciparum* from infected *Anopheles* mosquitoes

The *P. falciparum*-positive DNA samples were used as templates to nested amplify a portion of the *kelch13* gene encompassing the propeller domain known to contain the key mutations mediating artemisinin resistance (Ariey, 2014; Ahouidi, 2021). The primary and nested PCR *k13* primers are found in Table 1: S1. For the primary PCR, 20  $\mu\text{L}$  of the final volume was constituted of 4  $\mu\text{L}$  of the genomic DNA extract; 0.51  $\mu\text{L}$  each forward and reverse primers; 0.12  $\mu\text{L}$  each kappa Taq enzyme (Kappa Biosystems, Wilmington, MA, USA) and dNTP mix; 0.75  $\mu\text{L}$   $\text{MgCl}_2$ , 1.5  $\mu\text{L}$  kappa Taq buffer, and 12.49  $\mu\text{L}$  distilled water. The thermocycling conditions include: initial denaturation at  $95^{\circ}\text{C}$  for 5 min, followed by 30 cycles each of 30 sec at  $95^{\circ}\text{C}$  (denaturation), 2 min at  $58^{\circ}\text{C}$  (primer annealing), 2 min sec at  $72^{\circ}\text{C}$  (elongation). This was followed by a 10 min final elongation at  $72^{\circ}\text{C}$ . The nested PCR followed the same protocol of master mix composition as the primary PCR. The

**Table 1**

Status of *Plasmodium* infection rate in the major *Anopheles* malaria vectors across Cameroon: (a) Head/thorax (HT), (b) Abdomen (Abd), (c) Whole mosquito (WM); where: N = number of mosquito samples examined; Falcip+= infection by *P. falciparum*; OVM+= infection by *P. ovale/vivax/malariae*; and Falcip+/OVM+= Co-infection by *Plasmodium falciparum* and *P. ovale/vivax/malariae*; AGAM = *An. gambiae* s.s.; AFUN = *An. funestus* s.s and ACOL = *An. coluzzii*.

Localities	<i>Anopheles</i> spp	Year(s) of collection	N	Total infection	Falcip+	OVM+	Falcip+/OVM+
<b>Head/Thorax: <i>Plasmodium</i> sporozoite infection rate</b>							
Bankeng	<i>An. gambiae</i>	2019	287	22 (7.7%) [5.6–10.3%]	20 (90.9%) [87.4–94.7%]	01 (4.6%) [2.2–7.6%]	01 (4.5%) [2.2–7.6%]
Bonaberi	<i>An. coluzzii</i>	2019	262	01 (0.4%) [0.1–0.6%]	01 (100%)	00 (0%)	00 (0%)
Elende	<i>An. funestus</i>	2019	1000	78 (7.8%) [6.8–11.1%]	68 (87.2%) [84.9–90.4%]	08 (10.3%) [8.1–13.5%]	02 (2.6%) [0.9–5.3%]
Elon	<i>An. funestus</i>	2019 & 2020	273	07 (2.6%) [1.4–4.5%]	07 (100%)	00 (0%)	00 (0%)
Gounougou	<i>An. coluzzii</i>	2019 & 2020	465	34 (7.3%) [6.6–12.0%]	23 (67.6%) [65.3–70.7%]	09 (26.5%) [23.5–28.6%]	02 (5.9%) [3.3–8.6%]
Mibellon	<i>An. funestus</i>	2019	640	88 (13.8%) [12.1–20.1%]	62 (70.5%) [67.1–73.4%]	21 (23.9%) [20.6–25.0%]	05 (5.7) [3.4–7.1%]
Simatou	<i>An. coluzzii</i>	2019 & 2020	372	21 (5.7%) [4.2–8.5%]	20 (95.2%) [92.6–97.9%]	01 (4.8%) [2.1–6.4%]	00 (0%)
<b>Abdomen: <i>Plasmodium</i> oocyst infection rate</b>							
Bonaberi	<i>An. coluzzii</i>	2019	372	04 (1.1%) [0.7–2.7%]	04 (100%)	00 (0%)	00 (0%)
Elende	<i>An. funestus</i>	2019	434	47 (10.8%) [8.9–15.4%]	44 (93.6%) [90.5–95.5%]	03 (6.4%) [3.7–9.4%]	00 (0%)
Elon	<i>An. funestus</i>	2019	378	28 (7.4%) [7.3–9.0%]	26 (92.9%) [89.0–95.9%]	02 (7.1%) [5.4–9.6%]	00 (0%)
Gounougou	<i>An. coluzzii</i>	2019 & 2020	558	29 (5.2%) [3.8–8.8%]	20 (68.9%) [65.9–70.4%]	07 (24.1%) [21.9–27.7%]	02 (6.9%) [4.2–8.5%]
Mangoum	<i>An. gambiae</i>	2019 & 2020	465	51 (10.9%) [9.9–12.9%]	46 (90.2%) [87.9–92.0%]	05 (9.8%) [7.0–11.3%]	00 (0%)
Mibellon	<i>An. funestus</i>	2019	372	93 (25.0%) [23–27%]	56 (60.2%) [58.2–62.1%]	35 (37.6%) [35.9–40.5%]	02 (2.2%) [0.9–4.5%]
Simatou	<i>An. coluzzii</i>	2019 & 2020	465	25 (5.4%) [5.2–5.6%]	21 (84%) [81–86%]	04 (16%) [14–18%]	00 (0%)
<b>Whole mosquito: <i>Plasmodium</i> infection rate</b>							
Obout	<i>An. funestus</i>	2016	186	72 (38.7%) [35.7–41.4%]	57 (79.2%) [76.1–82.6%]	09 (12.5%) [10.0–14.5%]	06 (8.33%) [6.2–10.4%]

thermocycling parameters were the same except for the annealing temperature at 59 °C for 30 sec and 35 cycles increment.

Similarly, a nested PCR approach was used for amplification of codons 86 and 184 fragments of the *mdr1* gene (Agomo, 2016). The primary and nested *mdr1* PCR primers are included in Table 1: S1. The traditional primary and nested *mdr1* PCR master mix composition was similar to that of the *k13* protocol. The thermocycling profile was: initial denaturation at 95 °C for 5 min, proceeded by 30 cycles each of 30 sec at 94 °C, 45 sec at 45 °C, 1 min at 72 °C, and a final elongation of 10 min for 72 °C. The nested PCR protocol was the same like the primary except for the annealing temperature at 52 °C for 45 sec and 35 cycles addition. After amplification, the nested PCR products of both genes were each separated in 2% agarose gel. Furthermore, 10 µL PCR products each of the samples that correctly amplified were purified by the Exo-SAP protocol [New England Biolabs (NEB, MA, and USA)]. At most 20 (range: 4–20) randomly selected amplified *Pfk13* and *Pfmdr1* samples each from the HT and Abd body parts (depending on the infection rate) of the *Anopheles* mosquitoes from all the localities were directly sequenced.

## 2.5. Data analysis

The sporozoite and oocyst infection rates for the major *Anopheles* vectors across the 09 localities in Cameroon were analyzed in GraphPad Prism V8 (GraphPad Software, La Jolla California USA). A Chi-square test was used to determine the differences between categorical variables of stage-specific *Plasmodium* infection prevalence in each *Anopheles* vector per the locality. On the other hand, genomic sequence analysis commenced with a visual inspection of the qualities of the DNA sequence chromatograms and FASTA file using Chromas V.2.5 and Bioedit V.7.2.5 software respectively (Hall, 1999). The trimmed sequences were aligned to the *Pfk13* (PF3D7\_1343700) and *Pfmdr1*

(PF3D7\_0523000) reference sequences in PlasmoDB (www.Plasmodb.org) and examined for polymorphisms using ClustalW tool. A consensus forward sequence for each parasite population according to the body part (HT, Abd and Whole) and *Anopheles* species was generated with Bioedit software. Nucleotide sequences were translated *in silico* to complementary amino acids using the appropriate open reading frame in Mega X version 10.1.6 (Kumar et al., 2016) to identify the relevant single nucleotide polymorphism (SNP). A cladogram was built using the Maximum Likelihood method and Tamura-3 model, with a bootstrap factor of 1000 replicates. DNA polymorphisms were generated in dnaSP V.6.12.03 (Librado and Rozas, 2009). Haplotype networks were constructed using a combination of Arlequin 3.5.2.2. (Excoffier et al., 2005) and PopART (Leigh and Bryant, 2015) software.

## 3. Results

### 3.1. Species identification

Extraction of genomic DNA was done for a total of 6529 individual *Anopheles* mosquito samples (HT, Abd, and WM) across 09 localities in Cameroon (Table 1). Molecular speciation on a sub-set of 93 randomly extracted mosquito DNA samples across the 09 localities confirmed the dominance of *An. gambiae* s.s. in Bankeng [98.9% (92/93)] and Mangoum [100% (93/93)], *An. coluzzii* in Bonaberi [97.9% (91/93)], Gounougou [81.7% (76/93)] and Simatou [86.0% (80/93)]; and *An. funestus* s.s in Elende [97.8% (91/93)], Elon [93.5% (87/93)], Mibellon [98.9% (92/93)] and Obout [100% (93/93)].

### 3.2. Comparative Plasmodium infection rate in the head/thorax, abdomen, and whole mosquito of the major malaria vectors

The analysis of the head and thorax (HT) and abdomen (Abd) of the *Anopheles* mosquitoes across the 09 localities reveals a varying *Plasmodium* sporozoite and oocyst infection rate (Table 1; Fig. 2). Generally, sporozoite infection rates ranged from 0.4% (1/262) in *An. coluzzii* to 7.7% in *An. gambiae* and 13.8% (88/640) in *An. funestus*. The predominant species was *P. falciparum* with a frequency ranging from 67.7% to 100%. Meanwhile, OVM + vary from 0% to 26.5% and mix infection spanned from 0% to 5.9% (Table 2). Similar pattern was observed for oocyst infection rates although at a higher level. This ranges from 1.1% (4/372) in *An. coluzzii* to 25% (93/372) in *An. funestus*. *P. falciparum* was the main species with a frequency ranging from 60.2% to 100%. Likewise, the OVM + infection ranges from 0% to 37.6% while mix infection vary from 0% to 6.9% (Table 1). In whole body *An. funestus* samples from Obout, the *Plasmodium* infection rate was 38.7% (72/186) with 79.2% *P. falciparum*, 12.5% OVM + and 8.3% mix infection.

Overall, *An. funestus* population from Mibellon exhibited the highest *P. falciparum* and *P. malariae* sporozoite and oocyst infection rates while the least infection rate was recorded in *An. coluzzii* population from Bonaberi (Table 1). Moreover, a significant difference was observed between mosquitoes infected with *Plasmodium* oocyst and those with the infective sporozoite stage in Mibellon ( $\chi^2 = 2.4$ ;  $P < 0.05$ ), Elende ( $\chi^2 = 3.9$ ;  $P < 0.05$ ) and Elon ( $\chi^2 = 5.6$ ;  $P < 0.05$ ). In addition, mosquitoes collected using the techniques of indoor aspiration (*Plasmodium* Infection Rate (PIR) = 18.8%) and pyrethrum spray catch (PSC) (PIR = 7.1%) yielded a high *Plasmodium* infection rate than mosquitoes collected by HLC (PIR = 3.8%) (Table 2: S1).

### 3.3. Detection of polymorphisms in the Pfk13 propeller domain (k13PD) and mdr1 gene fragments

An 830 bp fragment of *Pfk13* gene encompassing the  $\beta$ -propeller domains (codons 443 – 705, 789 coding sequence) was successfully amplified (Fig. 1a: S1) from 171 *Pfk13* samples (88 Abd, 69H/T and 14 WM) (Table 3a: S1). Out of the 171 *P. falciparum* sequences, 158 were similar to the 3D7 reference. Three unique point mutations were observed in four oocyst-infected *Anopheles* abdomen sequences

including G450R (2.2%) in *An. gambiae*, G453D (2.2%) and L663L (4.4%) in *An. funestus* meanwhile the N458D (2.9%) and L663L (2.9%) were observed in two sporozoite infected H/T *An. funestus* sequences (Table 2a). The A578S mutation was present in both the oocyst and sporozoite sequences of *An. funestus*. Also, the R575I (4.4%) was present in two *P. falciparum* oocyst sequences of *An. funestus* but absent at the sporozoite stage (Table 2a). In addition, ambiguous polymorphisms were present only in *P. falciparum* oocyst sequences including L462(L/L) in *An. gambiae* and S466(S/T) in *An. funestus*. None of the WHO-validated or candidate *Pfk13* polymorphisms associated with artemisinin resistance were identified (Table 2a).

Similarly, a 570-base pair of the *mdr1* gene portion covering locus 86–184 (ranging from nucleotide position 121–597) was amplified from DNA extracts of *P. falciparum* infected HT, Abd and whole mosquito samples across the various localities (Fig. 1b: S1). A total of 193 *Pfmdr1* samples (93 Abd, 80 HT and 20 WM) were sequenced successfully (Table 3b: S1). Generally, the prevalence of circulating *P. falciparum* parasites harboring the mutant N86Y and Y184F non-synonymous polymorphisms were 5.4% and 60.2% in the oocyst stage; 17.5% and 67.5% in the sporozoite and 5% and 65% in the mixed stages from whole body respectively (Table 2b). Contrasting frequencies of the 86Y and 184F alleles were observed (Fig. 3 & Table 2b), indicative of the selection created by the major ACT, notably Artemether-Lumefantrine (AL) on the parasite genome. The presence of the double mutant haplotype YF was 5.4%, 16.3% and 5% in the oocyst, sporozoite and mixed stages from whole body respectively, with no significant difference observed across the different *Anopheles* populations. Additionally, the single mutant haplotype NF was the most predominant with a prevalence of 45.2%, 36.3% and 30% in the oocyst, sporozoite and mixed stages from whole body respectively. The NY haplotype occurred at a frequency of 20.4%, 16.3% and 15% in the oocyst, sporozoite and mixed stages from whole body respectively while the YY haplotype was absent (Table 4b: S1). Interestingly, a novel emerging variant, V62L was observed at low frequency in the abdomen (6.4%) and H/T (2.5%) alongside other minor synonymous polymorphisms (H53H, G102G and H143H) (Table 4a: S1).




Fig. 2. *Plasmodium* infection rate in the major *Anopheles* malaria vectors across Cameroon: (a) Head/thorax (HT), (b) Abdomen; where: Falcip+= infection by *P. falciparum*; OVM+= infection by *P. ovale/vivax/malariae*; Falcip+/OVM+= Co- infection by *Plasmodium falciparum* and *P. ovale/vivax/malariae*; AGAM = *An. gambiae* s.s; AFUN = *An. funestus* s.s and ACOL = *An. coluzzii*. Error bars represent standard error of the mean.

**Table 2**

Key synonymous (S) and non-synonymous (NS) single-nucleotide polymorphisms in *P. falciparum* drug resistance markers from infected *Anopheles* mosquitoes across Cameroon: **a.** *k13* β propeller domain and **b.** *mdr1* gene fragments.

Gene	Body part	<i>Anopheles</i> spp	Codon position	Wild sequence		Mutant sequence		Amino acid Product	Type	Frequency (%)	n/N		
				Amino acid	Nucleotide	Amino acid	Nucleotide						
<i>Pfk13</i>	Abdomen (Midgut)	AGAM	1348	G	GGA	R	AGA	G450R	NS	2.2	1/45		
			1358	G	GGT	D	GAT	G453D	NS	2.2	1/45		
		AFUN	1724	R	AGA	I	ATA	R575I	NS	4.4	2/45		
			1732	A	GCT	S	TCT	A578S	NS	2.2	1/45		
			1987	L	CTA	L	TTA	L663L	S	4.4	2/45		
	HT (Salivary gland)	AFUN	1372	N	AAT	D	GAT	N458D	NS	2.9	1/34		
			1732	A	GCT	S	TCT	A578S	NS	2.9	1/34		
			1987	L	CTA	L	TTA	L663L	S	2.9	1/34		
			<b><i>Pfmdr1</i></b>										
			<b><i>Anopheles</i> vector</b>										
N		Oocyst stage (Abdomen)											
		V62L n (%)			N86Y n (%)			Y184F n (%)					
		Wild (62V)	Mutant (62L)	Mixed (62V/L)	Wild (86N)	Mutant (86Y)	Mixed (86N/Y)	Wild (184Y)	Mutant (184F)	Mixed (184Y/F)			
ACOL	29	28 (96.6)	1(3.5)	0 (0)	26 (89.7)	1 (3.5)	2 (6.9)	10 (34.5)	15 (51.7)	4 (13.8)			
AGAM	16	16 (100)	0 (0)	0 (0)	13 (81.3)	1 (6.3)	2 (12.5)	0 (0)	8 (50)	8 (50)			
AFUN	48	42 (87.5)	5 (10.4)	1 (2.1)	40 (83.3)	3 (6.3)	5 (10.4)	9 (18.8)	33 (68.8)	6 (12.5)			
All	93	86 (92.5)	6 (6.4)	1 (1.1)	79 (84.9)	5 (5.4)	9 (9.7)	19 (20.4)	56 (60.2)	18 (19.4)			
<b>Sporozoite stage (H/T)</b>													
ACOL	23	22 (95.7)	1 (4.3)	0 (0)	15 (65.2)	4 (18.2)	4 (17.4)	3 (13.0)	19 (82.6)	1 (4.3)			
AGAM	17	17 (100)	0 (0)	0 (0)	11 (64.7)	3 (17.6)	3 (17.6)	3 (17.6)	11 (64.7)	3 (17.6)			
AFUN	40	39 (97.5)	1 (2.5)	0 (0)	29 (72.5)	7 (17.5)	4 (10)	7 (17.5)	24 (60)	9 (22.5)			
All	80	78 (97.5)	2 (2.5)	0 (0)	55 (68.8)	14 (17.5)	11 (13.8)	13 (16.3)	54 (67.5)	13 (16.3)			
<b>Total Plasmodium (Whole body)</b>													
AFUN	20	0 (0)	0 (0)	6 (30)	13 (65)	1 (5)	6 (30)	3 (15)	13 (65)	4 (20)			

**Note:** The boldface highlights the nucleotide base change. **Abbreviations:** n = number of samples containing mutant allele; N = total number of successfully sequenced samples; NS = non-synonymous mutation; S = synonymous mutation; ***Pfk13* polymorphisms:** A = Alanine, S = Serine, G = Glycine, R = Arginine, L = Leucine, D = Aspartic acid, I = Isoleucine, N = Asparagine. ***Pfmdr1* polymorphisms:** Y = Tyrosine, F = Phenylalanine, V = Valine, H = Histidine.

**Table 3a**

Polymorphism and genetic diversity parameters of *k13* drug resistance marker in natural *P. falciparum* populations circulating in the head/thorax and abdomen of major *Anopheles* vectors across Cameroon.

Body part	Species	Gene	2(n)	S	H	Hd	Pi	TajimaD	FuLiD	FuLiF
Abdomen (Diploid oocyst); 2n	ACOL	<i>k13</i>	56	0	1	0	0	0	0	0
	AGAM		30	2	3	0.191	0.00025	-1.25553	-0.73747	-1.02054
	AFUN		90	6	8	0.248	0.00041	-1.65933	-0.75796	-1.24546
	All		176	8	10	0.163	0.00026	-1.91573*	-1.39175	-1.87876
Head/Thorax (Haploid sporozoite); 2n*	ACOL		40	1	2	0.050	0.00006	-1.12411	-1.77404	-1.83507
	AGAM		30	0	1	0	0	0	0	0
	AFUN		68	4	5	0.195	0.00026	-1.61083	-0.17526	-0.73353
	All		138	5	6	0.113	0.00015	-1.76645	-1.19624	-1.63960
Abdomen (oocyst) + Head/Thorax (sporozoite)	ACOL		96	1	2	0.021	0.00003	-1.03241	-2.02060	-2.00827
	AGAM		60	2	3	0.098	0.00013	-1.31528	-0.94290	-1.22624
	AFUN		158	8	10	0.225	0.00035	-1.83601*	-1.34976	-1.80964
	All		314	11	13	0.141	0.00021	-2.05516*	-2.52346*	-2.82689*
Whole mosquito; 2n* (mixed oocyst + sporozoite stages)	AFUN		28	0	1	0	0	0	0	0

**Abbreviations:** n = number of sequences; S = number of polymorphic sites; H = haplotype; Hd = haplotype diversity; π = nucleotide diversity; TajimaD = Tajima's D statistic; FuLiD\* = Fu and Li's D\* statistic; FuLiF\* = Fu and Li's F\* statistic; \* = significant. AGAM = *An. gambiae* s.s.; AFUN = *An. funestus* s.s and ACOL = *An. coluzzii*. 2n\* = Sequences were unphased because of the observed heterozygosity (note: *P. falciparum* is haploid during the sporozoite stage (HT) of the mosquito. However, manual observation of the H/T *mdr1* sequences revealed a high heterozygosity. Thus, the sequences were unphased to have a detailed picture of the mixed alleles present in the sequences. This observed heterozygosity could be due to parasites originating from different tribal lineages or as a result of the high copy number variation of this gene).

**3.4. Genetic variability of the *Pfk13* propeller gene in major *Anopheles* vectors across Cameroon**

Analysis of the 789-bp fragment of the *k13* propeller domains from 88P. *falciparum* oocyst infected *Anopheles* abdomen sequences revealed the existence of ten distinct haplotypes (Table 3a). Generally, eight (8) polymorphic sites were detected with a haplotype diversity of 0.163. The dominant wild haplotype (H1) scored a high frequency of 91.5% (161/176) (Fig. 4a & 4b) while the remaining haplotypes constituting the mutant sequences recorded a low frequency including the H2 (0.6%,


1/176), H3 (1.1%, 2/176), H6 (0.6%, 1/176), H7 (0.6%, 1/176), H8 (2.3%, 4/176), H9 (0.6%, 1/176) and H10 (1.1%, 2/176) in *An. funestus*. The H4 (0.6%, 1/176) and H5 (1.1%, 2/176) haplotypes were documented in *An. gambiae* (Fig. 4b). Sequences congregate according to the presence of mutation, with the sequences containing mutations distancing away from sequences of H1. Deviation from the neutrality test of Tajima's D had a significant negative value (D = -1.91573\*) indicating an excess of rare alleles in the population (Table 3a). A maximum likelihood (ML) tree of the sequences analyzed confirms the low diversity with three major clusters (Fig. 4a). The wild type

**Table 3b**

Polymorphism and genetic diversity parameters of *mdr1* codons 86 & 184 drug resistance marker in natural *P. falciparum* populations circulating in the head/thorax, abdomen and whole body of the major *Anopheles* vectors across Cameroon.

Body part	Species	Gene	2(n)	S	H	Hd	Pi	TajimaD	FuLiD	FuLiF
Abdomen (Diploid oocyst); 2n	ACOL	<i>mdr1</i>	58	5	7	0.656	0.00187	-0.77269	-0.60065	-0.76994
	AGAM		32	3	4	0.573	0.00154	-0.03430	0.94181	0.76400
	AFUN		96	4	6	0.618	0.00186	-0.19123	1.04021	0.75155
	All		186	6	10	0.626	0.00183	-0.59191	1.14595	0.64412
Head/Thorax (Haploid sporozoite); 2n*	ACOL		46	6	9	0.704	0.00201	-0.77528	0.33477	-0.01513
	AGAM		34	2	3	0.658	0.00168	1.26352	0.79033	1.07038
	AFUN		80	5	6	0.668	0.00197	-0.15261	1.05574	0.78249
	All		160	7	11	0.673	0.00192	-0.57314	1.15765	0.66449
Abdomen (oocyst) + Head/Thorax (sporozoite)	ACOL		104	8	13	0.683	0.00203	-1.08841	-0.95047	-1.18445
	AGAM		66	3	4	0.621	0.00161	0.42848	0.86413	0.85268
	AFUN		176	6	8	0.646	0.00192	-0.53471	1.15025	0.67236
	All		346	9	17	0.652	0.00189	-0.92186	1.28984	0.56723
Whole mosquito; 2n* (mixed oocyst + sporozoite stages)	AFUN		40	2	3	0.610	0.00149	0.97432	0.77124	0.96165

**Abbreviations:** n = number of sequences; S = number of polymorphic sites; H = haplotype; Hd = haplotype diversity;  $\pi$  = nucleotide diversity; TajimaD = Tajima's D statistic; FuLiD\* = Fu and Li's D\* statistic; FuLiF\* = Fu and Li's F\* statistic; \* = significant; 2n\* = Sequences were unphased because of the observed high heterozygosity associated with gene copy number variation. AGAM = *An. gambiae* s.s; AFUN = *An. funestus* s.s and ACOL = *An. coluzzii*.



**Fig. 3.** Frequency of key *mdr1* mutant variants in the sporozoite (head/thorax) and oocyst (abdomen) of *P. falciparum* infected *Anopheles* vectors across Cameroon: (a) Sporozoite stage, (b) Oocyst stage; where: 62 V/L = Mixed alleles at locus 62; 62L = mutant allele at locus 62; 86 N/Y = Mixed alleles at locus 86; 86Y = Mutant allele at locus 86; 184Y/F = Mixed alleles at position 184 and 184F = Mutant allele at position 184; AGAM = *An. gambiae* s.s; AFUN = *An. funestus* s.s and ACOL = *An. coluzzii*. Error bars represent standard error of the mean.


sequences dominated as the most representative group followed by two mutant allele clusters in *An. funestus* (Fig. 4a). The remaining discrete cluster represents the mutant *P. falciparum* sequences from *An. gambiae* and *An. funestus*. Moreover, the haplotype network tree analysis revealed that haplotypes H2 to H10 are separated by a single mutation step from the ancestral haplotype H1 (Fig. 4b).

Polymorphism analyses of *P. falciparum* sporozoites in the H/T of infected *Anopheles* mosquitoes across Cameroon revealed a reduced haplotype diversity of 0.113 and five (5) polymorphic sites (Table 3a). Six (6) haplotypes were identified with the superior haplotype, H1 (94.2%, 130/138) representing the wild type population backbone. The remaining haplotypes representing the mutant sequences recorded a low frequency including: H2 (1.5%, 2/138), H3 (1.5%, 2/138), H5 (1.5%, 2/138) and H6 (0.7%, 1/138) in *An. funestus* from Elende; H4 (0.7%, 1/138) in *An. coluzzii* (Fig. 5a & b). The R575I mutation was absent in the H/T sporozoite sequences. Also, a reduction in the number of *k13* haplotypes between the oocyst (abdomen; n = 10) and sporozoite (H/T; n = 6) ( $\chi^2 = 3.0$ ;  $p = 0.02$ ) was observed. Phylogenetic analysis confirmed three distinct haplo-groups with the major haplotype being the wild-


type sequences and the other bearing the five minor mutant sequences (Fig. 6a). Furthermore, the neutrality population inference statistic of Tajima D ( $D = -1.76645$ ), FuLiD ( $-1.19624$ ) and FuLiF ( $-1.63960$ ) tests were all negative possibly indicating presence of rare alleles driven by a strong selection pressure (Table 3a). Similarly, the separation of H2 to H6 minor haplotypes from the parental major haplotype by one mutational line (Fig. 5b) highlights the independent emergence of these alleles. On the other hand, maximum likelihood and haplotype analysis of 28 *P. falciparum* isolates in *An. funestus* whole mosquito sequences from Obout showed the presence of only one polymorphic site and a single haplotype comprising of the wild type sequences. Tajima D and FuLiD variables were all zero (Table 3a).

### 3.5. Polymorphism analysis of the *Pfmdr1* gene fragments in the major *Anopheles* vectors across Cameroon

Six polymorphic sites (6) and ten haplotypes were detected across seven localities. The haplotype diversity was 0.626 (Table 3b). The predominant haplotype, H3, comprised exclusively of populations



**Fig. 4.** Pattern of genetic variability and polymorphism of the k13 propeller gene in natural *P. falciparum* populations circulating in the oocyst (abdomen) of the major *Anopheles* vectors across Cameroon. **a.** Phylogenetic tree analysis of the k13 propeller domain by maximum-likelihood with Tamura 3-parameter (T92) model. **b.** Haplotype network.




**Fig. 5.** Pattern of genetic variability and polymorphism of the k13 propeller gene in natural *P. falciparum* populations circulating in the sporozoite (H/T) of the major *Anopheles* vectors across Cameroon. **a.** Phylogenetic tree analysis of the k13 propeller domain by maximum-likelihood with Tamura 3-parameter (T92) model. **b.** Haplotype network revealing low polymorphisms.

harboring the 184F resistant allele backbone occurring at a frequency of 56.9% (106); followed by the H2 haplotype representing only the wild type allele at a proportion of 18.8% (35) (Fig. 6b). Haplotypes, H1 (6.9%, 13) comprises only the 62L allele while H4 (10.8%, 20) is a mix of the 86Y and the 184F resistant variant backbones. Co-existing haplotypes including the H5, H6, H7, H8, H9 and H10 occurred at a minor

frequency of 2.2% (4), 1.1% (2), 1.1% (2), 1.1% (2), 0.5% (1) and 0.5% (1) respectively (Fig. 6b). Proximity to the neutrality statistic of Tajima's D had a negative score ( $D = -0.59191$ ) indicating both population expansion and emergence of rare alleles owing to strong ACT pressure. A phylogenetic tree plot of the sequences circulating in the abdomen reveals six major clusters with the key 184F, 86Y and 62L backbones each






**Fig. 6.** Pattern of genetic variability and polymorphism of the *mdr1* gene fragments in natural *P. falciparum* populations circulating in the oocyst (Abdomen) of the major *Anopheles* vectors across Cameroon. a. Phylogenetic tree analysis of the *mdr1* gene fragments by maximum-likelihood with Tamura 3-parameter (T92) model. b. Haplotype network for the *mdr1* gene.

forming a group (Fig. 6a). The haplotype network tree shows that the mutation emerged as a result of parasite gene flow events facilitated by human and vector mobilities. This is evident based on the fact that shared haplotypes were observed in all the three major *Anopheles* vectors (Fig. 6a).

Polymorphism analyses of unphased *P. falciparum* sporozoites in the

H/T of infected *Anopheles* mosquitoes in six localities across Cameroon revealed a haplotype diversity of 0.673 with eight polymorphic sites (Table 3b). A total of eleven (11) haplotypes were identified with the major haplotype H1 (48.8%, 78/160) solely harboring the 184F resistant backbone (Fig. 7b). H2 (21.9%, 35) was shared between 184F and 86Y alleles and H3 (21.3%, 34) was a mixture of wild type and the



**Fig. 7.** Pattern of genetic variability and polymorphism of the *mdr1* gene fragments in natural *P. falciparum* populations circulating in the sporozoite (HT) of the major *Anopheles* vectors across Cameroon. a. Phylogenetic tree analysis of the *mdr1* gene fragments by maximum-likelihood with Tamura 3-parameter (T92) model. b. Haplotype network revealing dominance of the Y184F haplotype.

mutant haplotypes (86 N and 184F). Haplotypes, H5, H6 and H9 harbored the 62L allele (2.5%, 4) while H4, H7, H8, H10 and H11 occurred at minor frequencies of 1.3% (2), 0.6% (1), 1.3% (2), 1.3% (2) and 1.3% (2) respectively (Fig. 7b). Phylogenetic analysis confirms four distinct haplotype groups with the main haplotype being the 184F resistant assemblage alongside the one sub-major 86Y resistant parasites backbone (Fig. 7a). Furthermore, the neutrality population inference statistic of Tajima D ( $D = -0.57314$ ) was negative alongside a positive FuLiD (1.15765) and FuLiF (0.66449) tests (Table 3b). As previously indicated, the negative Tajima D implies a significant expansion of the mutant parasite population driven by a strong selection pressure. Similar results were observed for the whole *P. falciparum* infected *An. funestus* population (Table 3b) with three major haplotypes observed (Fig. 2a & 2b: S1). Further analysis combining both the oocyst (abdomen) and sporozoite (H/T) population reveals 17 circulating haplotypes with 07 distinct phylogenetic groups (Table 3b).

#### 4. Discussion

In the pursuit to control malaria, understanding the processes governing transmission of parasites between *Anopheles* vector and humans is fundamental (Bompard, 2020). This is particularly relevant in the Cameroon context where heterogeneous malaria transmission across diverse bioecological landscapes (Antonio-Nkondjio, 2019) is driven by many factors including the *Plasmodium* infection rate in genetically diverse *Anopheles* vectors. To this effect, anti-malaria drugs are heavily deployed to tackle the parasite population in an effort to minimize transmission. Such massive intervention of anti-malaria drugs is the major driving selection force of parasite evolutionary adaptation particularly for *P. falciparum* (Menard and Dondorp, 2017). This ultimately leads to the emergence of drug resistance alleles which are transmitted by *Anopheles* vectors to humans during an infectious blood meal. Currently, surveillance for *P. falciparum* markers mediating resistance to artemisinin and partner drugs is mostly based on parasite genotyping from positive human blood samples by microscopy (Uwimana, 2021). However, naturally infected mosquitoes are rarely utilized despite being the definitive host where sexual recombination occurs, producing a mixture of phenotypes. Here, genomic phenotyping of *P. falciparum* DNA from field-caught *Anopheles* mosquitoes across Cameroon was performed to investigate the possible emergence of mutations involved in artemisinin resistance and to determine the frequency of the *mdr1* alleles implicated in partner drug tolerance. This study provides data on the *Plasmodium* infection rate and polymorphism profile of molecular markers mediating drug resistance in *P. falciparum* infected *Anopheles* mosquitoes driving malaria transmission across Cameroon.

##### 4.1. High *Plasmodium* infection rates of major *Anopheles* vectors across Cameroon suggest a heterogeneous malaria transmission across diverse ecological biotopes

Despite the widespread distribution and overall impact of long-lasting insecticide treated nets, there still exists a significant variation in *Plasmodium* infection prevalence in the major malaria vectors across Cameroon (Antonio-Nkondjio, 2019; Tchouakui, 2019). The infection rate which is a key component of the entomological inoculation index determines the local patterns of malaria transmission (Antonio-Nkondjio, 2019). The heterogeneity in the observed *Plasmodium* infection rates per each eco-geographical landscape translates to the vectorial competence of the dominant vectors. Villages located within the equatorial facets (Bankeng, Elende, Mangoum and About), sudano-guinean belt (Mibellon and Gounougou) and Sahelian zone (Simatou) where *An. funestus*, *An. gambiae* and *An. coluzzii* are generally the principal vectors recorded high sporozoite infection rates. This could be as a result of high vector densities (The PMI VectorLink Project, A.A., 2020), high degree of pyrethroid resistance that encourages the tremendous anthropophilic

blood feeding tendency of the vectors and their ability to survive in nature (Tchouakui, 2019; Ndo, 2018). These factors favor the vectors' ability to potentially blood feed on the humans harboring high *Plasmodium* parasite loads thereby piloting the hyper-endemic malaria transmission pattern observed in these localities. However, a low sporozoite infection rate was observed in *An. coluzzii* population from Bonaberi where malaria transmission is hypo-endemic. This disparity could be attributed to a low parasite prevalence in the resident human population (Kojom Foko, 2021) and the transmission capacity of the local vector (Atangana, 2010). Moreover, the extensive circulation and use of drugs in this urban setting may contribute to shrinking the parasite population pool in humans (Waffo Tchounga, 2021). In particular, the high sporozoite infection rate scores of *An. funestus* provides further evidence on the major role played by this vector species in determining malaria transmission in Cameroon. This observed infection rate is similar to previous reports for this species in Cameroon (Tchouakui, 2019) and across Africa precisely in Benin (18%) (Djouaka, 2016) and Ghana (12.5%) (Riveron, 2016). This repeatedly high score of infection corresponds with a high vectorial capacity of this *Anopheles* species across Africa and poses a serious concern on the efficacy of interventions targeted at controlling malaria in high transmission areas.

##### 4.2. The impact of mosquito intrinsic defense system and midgut barriers in reducing the force of *Plasmodium* infection and malaria transmission

The marked reduction in the sporozoite infection rate relative to the oocyst infection rate notably for *An. funestus* population from Mibellon, Elon and Elende and *An. coluzzii* population from Bonaberi indicates the contribution of mosquito immune system checkpoints (Aly et al., 2009) in limiting both *P. falciparum* and *P. malariae* sporogonic development. Thus, exploiting mosquito immunity for possible design of transmission blocking interventions will complement efforts towards malaria elimination in Africa.

##### 4.3. Absence of artemisinin resistance markers in *P. falciparum* populations suggest the continued efficacy of artemisinin derivatives in Cameroon

The absence of the WHO validated *Pfk13* mutations (F446I, Y493H, R539T, I543T, P553L, R561H, P574L, C580Y, A675V, C469Y) (WHO, 2021; Uwimana, 2021; Balikagala, 2021; Ménard, 2016; Straimer, 2021) possibly reflects the continued efficacy of artemisinin derivatives in the treatment of malaria in Cameroon. Majority of SNPs in the *k13* protein of *P. falciparum* parasite population from African descent revolves particularly within the 400–600 amino acid coding region of the  $\beta$ -propeller domain (Ariey, 2014; Ménard, 2016), indicating that this region is particularly under strong selection owing to among others, intense ACT use over the years (Dondorp, 2009). This points attention to the R575I polymorphism detected at a low frequency in the oocyst (abdomen) of *An. funestus* mosquitoes from Mibellon. This mutation, previously observed in Rwanda at a much lower frequency has not yet been characterized (Uwimana, 2021), although it was observed not to be associated with artemisinin resistance in Rwanda parasite isolates (Uwimana, 2021). However, this R575I SNP is located five amino acids upstream of the C580Y and is also adjacent to the R561H mutation which are the key variants mediating Art-R in South-East Asia and Rwanda respectively. Secondly, like the R561H and C580Y SNPs (Uwimana, 2021; Ménard, 2016), the R575I mutation is interesting because Isoleucine, a neutral non-polar amino acid replaces Arginine, a basic polar amino acid. This substitutional change may affect the tertiary structure and thus the function of the propeller (Straimer, 2015). Nonetheless, the absence of this mutation in the sporozoite (H/T) of infected *An. funestus* mosquitoes may imply that mutation-induced fitness could be playing a vital role in limiting the transmission of mutant parasite phenotypes (Stokes, 2021). *P. falciparum* parasites harboring deleterious artemisinin resistant alleles could be less fit for survival compared to wild types and the probability

of their transmission is reduced. This is particularly relevant for rare *k13* mutations that may impose a huge survival cost for the parasite especially in high malaria transmission settings where competition with multiple parasite strains is common (Menard and Dondorp, 2017). This could explain the reason why the R575I mutation was present in the oocyst but absent in the sporozoite stage. This study highlights the viewpoint that regular monitoring for *de novo* emergence of potentially novel local variants and surveillance for the possible introduction of the resistance phenotype is necessary for tracking the emergence of artemisinin resistance and mapping resistance hotspots in Cameroon.

Furthermore, the A578S variant, commonly observed in different *P. falciparum* *k13* backgrounds across Africa has already been demonstrated not to be involved in artemisinin resistance (Ménard, 2016; Schmedes, 2021). This polymorphism was detected at a low frequency in the abdomen and H/T of two separate *An. funestus* mosquito from Elon. A recent study evaluating the clinical efficacy of dihydroartemisinin/piperazine in *P. falciparum* malaria subjects in Yaoundé (situated 50 Km from Elon), Centre Cameroon revealed a 2% (3/150) prevalence of the A578S mutation (Mairet-Khedim, 2021), further confirming the data obtained from this study. However, comparing previous studies in Cameroon that utilized *P. falciparum* infected blood samples from human subjects (Eboumbou Moukoko, 2019; Apinjoh, 2017), none of the *k13* polymorphisms detected in this study was similar. This could be attributed to many factors including, the wide variability of the polymorphism profile in the *k13* region, differences in parasite genotype complexity, sampling sites, period of sampling, local selection pressure, intensity of malaria transmission and level of immunity (Menard and Dondorp, 2017; Asua, 2021). Moreover, the fact that these three studies utilized *P. falciparum* human blood samples as opposed to infected *Anopheles* mosquitoes for molecular genotyping could reflect dissimilarities in both the human (intermediate) and *Anopheles* (definitive) host systems wherein parasites harboring lethal mutations may be eliminated during the sexual development in the mosquito. Also, the presence of the A578S polymorphism in both oocyst and sporozoite stages suggest a neutral effect and no fitness cost of this mutation associated with parasite transmission (Stokes, 2021). The significant negative D value suggests a possible recent *de novo* expansion of singleton polymorphisms in this gene across the parasite populations. No evidence of selection acting on the domain implies that ACTs pressure is minimally impacting on *k13*PD diversity in Cameroon. Generally, the *k13*PD locus exhibits a remarkable genomic sequence conservation across *Plasmodium* species (Conrad et al., 2019) and the fact that no fixed non-synonymous mutation was found in the domain indicates that this gene evolved under strong purifying selection; and that the rare variants observed in this study arose recently. Indeed, a large number of rare variants is characteristic of the genomes of African but not Asian *P. falciparum* parasites (Conrad et al., 2019).

#### 4.4. Directional selection of Y184F in combination with the N86Y allele alongside emerging novel variants may be compromising parasite susceptibility to ACTs

Mutations in the *Pfmdr1* gene is associated with decrease sensitivity to multiple antimalarial drugs including, amodiaquine, lumefantrine, halofantrine, mefloquine, chloroquine and artemether (Duraisingh, 2000; World Health Organization, 2019; Lekana-Douki and Boundenga, 2018). The high frequency of the <sup>86</sup>N<sup>184</sup>F alleles implies that *Pfmdr1* parasite mutants are selected and sustained in the population. This could be linked to the continuous deployment of first-line interventions; Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (ASAQ) for the treatment of uncomplicated malaria (Antonio-Nkondjio, 2019; Veiga, 2016). These observations correlate with similar findings in Cameroon where blood samples from human cohorts were used for resistance genotyping (L'Episcopia, 2021) and elsewhere in Africa where infected mosquitoes were the targeted group (Smith-Aguasca, 2019; Temu, 2006). A greater fraction of the parasites harbored the

184F allele at both oocyst (60.2%) and sporozoite (67.5%) stages. However, a disparity was observed for the 86Y resistant variant where a significant proportion ( $\chi^2 = 3.4$ ,  $P < 0.05$ ) of this allele was harbored by *P. falciparum* sporozoite population (17.5%) as compared to the oocyst population (5.4%). These differences reflect the opposing effects of AL and ASAQ. Indeed, studies have demonstrated that AL selects for both the N86-wild type and 184F-mutant haplotypes (<sup>86</sup>N<sup>184</sup>F) whereas ASAQ is associated with selection of the mutant 86Y and wild Y184 haplotypes (<sup>86</sup>Y<sup>184</sup>Y) (Mbaye, 2016; Venkatesan, et al., 2014). The predominance of the AL selected NF haplotype suggests its continuous selection over time; implying that these mutant parasites have better adapted and are more fit for transmission, and may constitute the dominant population involved in gametocytogenesis

Contrary to *k13* mutant phenotypes, parasites harboring the *mdr1* allele, Y18F may have a significant advantage due to the long-standing existence of resistance to the partner drug, further facilitated by decades of continuous drug use (World Health Organization, 2019; Mbaye, 2016). This creates an even stronger sustained selection pressure over time, consequently favoring transmission of these mutant parasite phenotypes. The detection of the V62L variant points to the view that the *mdr1* gene backbone could be evolving in some localities via the emergence of novel alleles as ACTs are continuously implemented. Nevertheless, the reduction in the frequency of the V62L novel allele from the oocyst to sporozoite stage notably in Mibellon and Elende *P. falciparum* infected *An. funestus* populations may reflect a possible fitness cost to enhanced clearance by mosquito immune mechanisms.

#### 4.5. Mosquito immune selection may be suppressing the spread of artemisinin drug resistance parasites while facilitating the transmission of AL selected parasite lineages

African malaria vectors particularly *An. gambiae* and *An. funestus* has been shown to mount high levels of innate immune response against the *Plasmodium* parasite especially after sexual recombination in the midgut (Clayton et al., 2014). Such intensity in the strength of immune selection may limit the survival of lethal *P. falciparum* drug resistant variant phenotypes while concomitantly bringing about a bottleneck reduction in oocyst loads (Smith and Barillas-Mury, 2016). In particular, genetic recombination can negatively impact the spread of artemisinin resistance alleles by breaking down resistance haplotypes (Mharakurwa, 2013). This therefore implies that mosquito immune selection may be delaying the development and spread of potentially dangerous drug resistance alleles in high transmission settings by favoring sensitive lineages to remain in the hemocoel circulation, particularly for *k13* polymorphisms involved in artemisinin resistance. In addition, the interspecific competition within genetically diverse parasite phenotypes may lead to the suppression of resistant lineages within *Anopheles* hosts (Mharakurwa, 2013).

However, as the occurrence of sexual recombination in the mosquito midgut produces a mixture of phenotypes; this may positively influence the spread of partner drug resistant alleles through transmission dependent mosquito selection of a particular haplotype known to potentiate parasite tolerance (e.g., <sup>86</sup>N<sup>184</sup>F for AL). Such traditionally resistant genetic variants may confer better adaptative potentials for parasite transmission. In addition, once resistance is common on many *P. falciparum* genetic backgrounds (notably for *mdr1*), mosquito immune selection can steadily maintain a particular resistance allele of the parasite to the existing drug (e.g., lumefantrine or amodiaquine) in the population. This eventually favors the multiplication and transmission of the resistant parasite phenotype. This could account for the dominance of the 184F resistant allele present in *P. falciparum* infected mosquitoes and reveals that this allele is under transmission-driven positive selection. This suggests that mosquito immune selection may be shaping the local pattern of drug resistance evolution and spread once resistance is widespread (Whitlock et al., 2021). This agrees with a previous study demonstrating that mosquitoes play a significant role in

determining the frequency of drug resistant *P. falciparum* population in natural (Mharakurwa, 2013; Mharakurwa, 2011; Temu, 2006) and experimental (Berry, 2021) settings.

Hence, in high malaria transmission settings, wild mosquitoes could be playing a key role in delaying the emergence and spread of artemisinin drug resistant parasites. Also, this study points to the view that interventions focusing on reducing mosquito abundance may indirectly influence the spread of drug resistant parasites by decreasing the *Anopheles* population that select on drug resistance polymorphisms (Mharakurwa, 2013). Additional investigation is required to assess the impact of mosquito immunity on the development and transmission of drug resistant parasites through experimental infection assays.

Although drug resistance xeno-surveillance of *P. falciparum* from the lens of the mosquito is a promising approach, there exist a few drawbacks. Firstly, detection of emerging selected *de novo* mutants linked particularly to artemisinin resistance could be more sensitive in the human host, contrary to the mosquito life cycle, where sexual recombination driven-negative selection against such mutants could occur (Vanaerschot, 2014). In spite of this, allele frequency estimate of resistance marker surveillance in the mosquito vector is reliably a more appropriate measure of resistance epidemiology since anti-malaria drug resistance presents a higher chance to be transmitted than acquired (Smith-Aguasca, 2019). Furthermore, these infected mosquitoes were mostly collected in high transmission settings, implying that xeno-monitoring approach may be less economical in a low malaria transmission area (e.g., Bonaberi) where screening of a considerable large number of mosquitoes has to be undertaken to detect both low-density infections and polymorphism counts. Notwithstanding, this is a common problem for resistance detection in low transmission settings, regardless of utilizing human or mosquito samples. In addition, TaqMan assay technique cannot distinguish the various non-falciparum species (*P. ovale*, *vivax* and *malariae*) in the infected mosquito samples. However, the utilization of nested PCR (Snounou, 1993) resolves this limitation by accurately discriminating the *Plasmodium* species.

## 5. Conclusion

Xeno-monitoring provides an alternative practical approach to the surveillance of *Plasmodium* parasite populations in *Anopheles* vectors, especially in high transmission settings. The high *P. falciparum* and *P. malariae* infection rates in *Anopheles* mosquitoes coupled with the dominance of the  $^{86}\text{N}^{184}\text{F}$  haplotype suggest an increase tolerance of *P. falciparum* to ACTs particularly Artemether-Lumefantrine and highlights the challenges of malaria control in Cameroon.

## Ethical approval

This study received institutional approval (NO 2020/05/1234/CE/CNERSH/SP) for HLC sampling from the Cameroon National Committee on Research Ethics for Human Health.

## Data availability statement

All the data from this study is present in the manuscript and supplementary file (Appendix A). All Pfk13 and mdr1 sequences in this study were deposited in the GenBank database (accession numbers - Pfk13: OM023056 - OM023397 and Pfmldr1: OM023398 - OM023783).

## Funding statement

This research was funded in whole by the Wellcome Trust [Grant No. 217188/Z/19/Z] awarded to CSW. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The funders had no role in the design, data collection, analysis, interpretation of the results, preparation of manuscript or decision to publish.

## CRediT authorship contribution statement

**Francis N. Nkemngo:** Methodology, Formal analysis, Investigation, Data curation, Writing – original draft, Writing – review & editing, Visualization. **Leon M.J. Mugenzi:** Investigation, Writing – review & editing. **Magellan Tchouakui:** Investigation, Writing – review & editing. **Daniel Nguiffo-Nguete:** Investigation, Writing – review & editing. **Murielle J. Wondji:** Resources, Writing – review & editing. **Bertrand Mbakam:** Resource, Writing - review & editing. **Micareme Tchoupo:** Resource, Writing – review & editing. **Cyrille Ndo:** Writing – review & editing, Supervision. **Samuel Wanji:** Writing – review & editing, Supervision. **Charles S. Wondji:** Conceptualization, Validation, Writing – review & editing, Visualization, Supervision, Project administration, Funding acquisition.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

The authors are grateful to the research team members at CRID particularly Doumani Djonabaye, Dr Delia Djuicy and Yvan Fotso for their scientific and graphical inputs and to Mr. Achille Binyang for providing the Bankeng mosquito samples. We also thank the village leaders and community members of the various localities for providing access to their houses to be used for mosquito sampling.

## Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.gene.2022.146339>.

## References

- Agomo, C.O., et al., 2016. Assessment of Markers of Antimalarial Drug Resistance in *Plasmodium falciparum* Isolates from Pregnant Women in Lagos, Nigeria. *PLoS ONE* 11 (1), e0146908.
- Ahouidi, A., et al., 2021. Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal. *PLoS ONE* 16 (3), e0249357.
- Akideh, N.M., et al., 2021. Assessing Asymptomatic Malaria Carriage of *Plasmodium falciparum* and Non-falciparum Species in Children Resident in Nkolbisson, Yaoundé, Cameroon. *Children* 8 (11), 960.
- Aly, A.S.L., Vaughan, A.M., Kappe, S.H.L., 2009. Malaria parasite development in the mosquito and infection of the mammalian host. *Annu. Rev. Microbiol.* 63, 195–221.
- Antonio-nkondjio, C., et al., 2006. Complexity of the Malaria Vectorial System in Cameroon: Contribution of Secondary Vectors to Malaria Transmission. *J. Med. Entomol.* 43 (6), 1215–1221.
- Antonio-Nkondjio, C., et al., 2019. Review of malaria situation in Cameroon: technical viewpoint on challenges and prospects for disease elimination. *Parasites Vectors* 12 (1), 501.
- Apinjoh, T.O., et al., 2017. Molecular markers for artemisinin and partner drug resistance in natural *Plasmodium falciparum* populations following increased insecticide treated net coverage along the slope of mount Cameroon: cross-sectional study. *Infect. Dis. Poverty* 6 (1), 136–136.
- Ariey, F., et al., 2014. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 505 (7481), 50–55.
- Asua, V., et al., 2021. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. *J. Infect. Dis.* 223 (6), 985–994.
- Atangana, J., et al., 2010. Anopheline fauna and malaria transmission in four ecologically distinct zones in Cameroon. *Acta Trop.* 115 (1–2), 131–136.
- Balikagala, B., et al., 2021. Evidence of Artemisinin-Resistant Malaria in Africa. *N. Engl. J. Med.* 385 (13), 1163–1171.
- Bass, C., et al., 2008. PCR-based detection of *Plasmodium* in *Anopheles* mosquitoes: a comparison of a new high-throughput assay with existing methods. *Malar. J.* 7 (1), 177.
- Beier, J.C., 1998. Malaria parasite development in mosquitoes. *Annu. Rev. Entomol.* 43 (1), 519–543.
- Bennink, S., Kiesow, M.J., Pradel, G., 2016. The development of malaria parasites in the mosquito midgut. *Cell. Microbiol.* 18 (7), 905–918.
- Berry, A., et al., 2021. The Rare, the Best: Spread of Antimalarial-Resistant *Plasmodium falciparum* Parasites by *Anopheles* Mosquito Vectors. *Microbiol. Spectrum.* 9 (2) e00852-21.

- Bhatt, S., et al., 2015. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature* 526 (7572), 207–211.
- Bompard, A., et al., 2020. High *Plasmodium* infection intensity in naturally infected malaria vectors in Africa. *Int. J. Parasitol.* 50 (12), 985–996.
- Chotivanich, K., et al., 2006. Transmission-blocking activities of quinine, primaquine, and artesunate. *Antimicrob. Agents Chemother.* 50 (6), 1927–1930.
- Clayton, A.M., Dong, Y., Dimopoulos, G., 2014. The *Anopheles* innate immune system in the defense against malaria infection. *J. Innate Immun.* 6 (2), 169–181.
- Coetzee, M., 2020. Key to the females of Afrotropical *Anopheles* mosquitoes (Diptera: Culicidae). *Malar. J.* 19 (1), 70.
- Conrad, M.D., Rosenthal, P.J., 2019. Antimalarial drug resistance in Africa: the calm before the storm? *Lancet. Infect. Dis* 19 (10), e338–e351.
- Conrad, M.D., Nsoya, S.L., Rosenthal, P.J., 2019. The diversity of the *Plasmodium falciparum* K13 propeller domain did not increase after implementation of artemisinin-based combination therapy in Uganda. *Antimicrob. Agents Chemother.* 63 (10), e01234–e1319.
- Djouaka, R., et al., 2016. Multiple insecticide resistance in an infected population of the malaria vector *Anopheles funestus* in Benin. *Parasites Vectors* 9 (1), 453.
- Dondorp, A.M., et al., 2009. Artemisinin Resistance in *Plasmodium falciparum* Malaria. *N. Engl. J. Med.* 361 (5), 455–467.
- Drakeley, C.J., et al., 2004. Addition of artesunate to chloroquine for treatment of *Plasmodium falciparum* malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. *Trop. Med. Int. Health* 9 (1), 53–61.
- Duraisingh, M.T., et al., 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the *pfmdr1* gene of *Plasmodium falciparum*. *Mol. Microbiol.* 36 (4), 955–961.
- Eboubou Moukoko, C.E., et al., 2019. K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian *Plasmodium falciparum* malaria patients. *PLoS ONE* 14 (9), e0221895.
- Ehrlich, H.Y., et al., 2021. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. *Proc. Natl. Acad. Sci.* 118 (29), e2100685118.
- Elanga-Ndille, E., et al., 2019. Overexpression of Two Members of D7 Salivary Genes Family is Associated with Pyrethroid Resistance in the Malaria Vector *Anopheles funestus* s.s. but Not in *Anopheles gambiae* in Cameroon. *Genes* 10 (3), 211.
- Elanga-Ndille, E., et al., 2019. The G119S Acetylcholinesterase (Ace-1) Target Site Mutation Confers Carbamate Resistance in the Major Malaria Vector *Anopheles gambiae* from Cameroon: A Challenge for the Coming IRS Implementation. *Genes* 10 (10), 790.
- Excoffier, L., Laval, G., Schneider, S., 2005. Arlequin (version 3.0): An integrated software package for population genetics data analysis. *Evolut. Bioinform.* 1, 117693430500100003.
- Fidock, D.A., Rosenthal, P.J., 2021. Artemisinin resistance in Africa: How urgent is the threat? *Med* 2 (12), 1287–1288.
- Foley, D.H., et al., 2012. Mosquito bisection as a variable in estimates of PCR-derived malaria sporozoite rates. *Malaria J.* 11 (1), 145.
- Fru-Cho, J., et al., 2014. Molecular typing reveals substantial *Plasmodium vivax* infection in asymptomatic adults in a rural area of Cameroon. *Malar. J.* 13, 170.
- Gillies, M., 1968. The Anophelinae of Africa south of the Sahara (Ethiopian zoogeographical region). *Publ. South Afric. Inst. Med. Res.* 54, 1–353.
- Hall, T., 1999. BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. *Nucl. Acids Symp. Ser.* 41, 95–98.
- Koekemoer, L.L., et al., 2002. A cocktail polymerase chain reaction assay to identify members of the *Anopheles funestus* (Diptera: Culicidae) group. *Am. J. Trop. Med. Hyg.* 66 (6), 804–811.
- Kojom Foko, L.P., et al., 2021. Prevalence, Patterns, and Determinants of Malaria and Malnutrition in Douala, Cameroon: A Cross-Sectional Community-Based Study. *Biomed. Res. Int.* 2021, 5553344.
- Kumar, S., Stecher, G., Tamura, K., 2016. MEGA X: molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Mole. Biol. Evol.* 33 (7), 1870–1874.
- L'Episcopia, M., et al., 2021. Targeted deep amplicon sequencing of antimalarial resistance markers in *Plasmodium falciparum* isolates from Cameroon. *Int. J. Infect. Dis.* 107, 234–241.
- Leigh, J.W., Bryant, D., 2015. popart: full-feature software for haplotype network construction. *Methods Ecol. Evol.* 6 (9), 1110–1116.
- Lekana-Douki, J.B., Boundenga, L., 2018. Genotyping for *Plasmodium* spp.: Diagnosis and Monitoring of Antimalarial Drug Resistance. In: *Genotyping*, 2018, IntechOpen.
- Librado, P., Rozas, J., 2009. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. *Bioinformatics* 25 (11), 1451–1452.
- Livak, K., 1984. Organization and mapping of a sequence on the *Drosophila melanogaster* X and Y chromosomes that is transcribed during spermatogenesis. *Genetics* 107, 611–634.
- Mairet-Khedim, M., et al., 2021. Efficacy of dihydroartemisinin/piperazine in patients with non-complicated *Plasmodium falciparum* malaria in Yaoundé, Cameroon. *J. Antimicrob. Chem.* 76 (11), 3037–3044.
- Mbaye, A., et al., 2016. Selection of N86F184D1246 haplotype of *Pfmdr1* gene by artemether-lumefantrine drug pressure on *Plasmodium falciparum* populations in Senegal. *Malar. J.* 15 (1), 433.
- Ménard, D., et al., 2016. A Worldwide Map of *Plasmodium falciparum* K13-Propeller Polymorphisms. *N. Engl. J. Med.* 374 (25), 2453–2464.
- Menard, D., Dondorp, A., 2017. Antimalarial drug resistance: A threat to malaria elimination. *Cold Spring Harbor Perspect. Med.* 7 (7), a025619.
- Menze, B.D., et al., 2016. Multiple insecticide resistance in the malaria vector *Anopheles funestus* from Northern Cameroon is mediated by metabolic resistance alongside potential target site insensitivity mutations. *PLoS ONE* 11 (10), e0163261.
- Menze, B.D., et al., 2018. Bionomics and insecticides resistance profiling of malaria vectors at a selected site for experimental hut trials in central Cameroon. *Malar. J.* 17 (1), 317.
- Mharakurwa, S., et al., 2011. Malaria antifolate resistance with contrasting *Plasmodium falciparum* dihydrofolate reductase (DHFR) polymorphisms in humans and *Anopheles* mosquitoes. *Proc. Natl. Acad. Sci.* 108 (46), 18796–18801.
- Mharakurwa, S., et al., 2013. Selection for chloroquine-sensitive *Plasmodium falciparum* by wild *Anopheles arabiensis* in Southern Zambia. *Malar. J.* 12 (1), 453.
- Ndo, C., et al., 2018. Elevated *Plasmodium* infection rates and high pyrethroid resistance in major malaria vectors in a forested area of Cameroon highlight challenges of malaria control. *Parasites Vectors* 11 (1), 157.
- Ngotho, P., et al., 2019. Revisiting gametocyte biology in malaria parasites. *FEMS Microbiol. Rev.* 43 (4), 401–414.
- Nkemngo, F.N., et al., 2020. Multiple insecticide resistance and *Plasmodium* infection in the principal malaria vectors *Anopheles funestus* and *Anopheles gambiae* in a forested locality close to the Yaoundé airport, Cameroon. *Wellcome Open Res.* 5.
- Noeld, H., et al., 2008. Evidence of Artemisinin-Resistant Malaria in Western Cambodia. *N. Engl. J. Med.* 359 (24), 2619–2620.
- Paul, R.E., Brey, P.T., Robert, V., 2002. *Plasmodium* sex determination and transmission to mosquitoes. *Trends Parasitol.* 18 (1), 32–38.
- Peatey, C.L., et al., 2012. Anti-malarial drugs: how effective are they against *Plasmodium falciparum* gametocytes? *Malar. J.* 11 (1), 34.
- Riveron, J.M., et al., 2016. Multiple insecticide resistance in the major malaria vector *Anopheles funestus* in southern Ghana: implications for malaria control. *Parasites Vectors* 9 (1), 504.
- Roman, D.N.R., et al., 2018. Asymptomatic *Plasmodium malariae* infections in children from suburban areas of Yaoundé, Cameroon. *Parasitol. Int.* 67 (1), 29–33.
- Santolamazza, F., et al., 2008. Insertion polymorphisms of SINE200 retrotransposons within speciation islands of *Anopheles gambiae* molecular forms. *Malar. J.* 7 (1), 163.
- Sawa, P., et al., 2013. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperazine: a randomized trial. *J. Infect. Dis.* 207 (11), 1637–1645.
- Schmedes, S., et al., 2021. *Plasmodium falciparum* kelch13 Mutations, 9 Countries in Africa, 2014–2018. *Emerg. Infect. Dis. J.* 27 (7), 1902.
- Smith, R.C., Barillas-Mury, C., 2016. *Plasmodium* Oocysts: Overlooked Targets of Mosquito Immunity. *Trends Parasitol.* 32 (12), 979–990.
- Smith, R.C., Jacobs-Lorena, M., 2010. *Plasmodium*–mosquito interactions: a tale of roadblocks and detours. *Adv. Insect Physiol.* 39, 119–149.
- Smith-Aguasca, R., et al., 2019. Mosquitoes as a feasible sentinel group for anti-malarial resistance surveillance by Next Generation Sequencing of *Plasmodium falciparum*. *Malar. J.* 18 (1), 351.
- Snounou, G., et al., 1993. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol. Biochem. Parasitol.* 61 (2), 315–320.
- Stokes, B.H., et al., 2021. *Plasmodium falciparum* K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. *eLife* 10, e66277.
- Straimer, J., et al., 2015. K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates. *Science* 347 (6220), 428–431.
- Straimer, J., et al., 2021. High prevalence of *P. falciparum* K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether–lumefantrine. *J. Infect. Dis.*
- Tabue, R.N., et al., 2019. Case Definitions of Clinical Malaria in Children from Three Health Districts in the North Region of Cameroon. *Biomed Res. Int.* 2019, 9709013.
- Tchouakui, M., et al., 2019. A marker of glutathione S-transferase-mediated resistance to insecticides is associated with higher *Plasmodium* infection in the African malaria vector *Anopheles funestus*. *Sci. Rep.* 9 (1), 5772.
- Temu, E.A., et al., 2006. Monitoring chloroquine resistance using *Plasmodium falciparum* parasites isolated from wild mosquitoes in Tanzania. *Am. J. Trop. Med. Hygiene* 75 (6), 1182–1187.
- The PMI VectorLink Project, A.A., 2020. The President's Malaria Initiative (PMI)-VectorLink Project. The PMI VectorLink Cameroon Annual Entomology Report. October 2018–September 2019. Rockville, MD.
- Uwimana, A., et al., 2021. Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda. *Nat. Med.* 27 (6), 1113–1115.
- Uwimana, A., et al., 2021. Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet. Infect. Dis* 21 (8), 1120–1128.
- Vanaerschoot, M., et al., 2014. Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race. *FEMS Microbiol. Rev.* 38 (1), 41–55.
- Veiga, M.I., et al., 2016. Globally prevalent PfMDR1 mutations modulate *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies. *Nat. Commun.* 7 (1), 1–12.
- Venkatesan, M., et al., 2014. Polymorphisms in *Plasmodium falciparum* chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for *P. falciparum* malaria after artemether-lumefantrine and artesunate-amodiaquine. *Am. J. Trop. Med. Hygiene* 91 (4), 833.
- Waffo Tchounga, C.A., et al., 2021. Poor-quality medicines in Cameroon: A critical review. *Am. J. Trop. Med. Hygiene* 105 (2), 284–294.
- Whitlock, A.O.B., Juliano, J.J., Mideo, N., 2021. Immune selection suppresses the emergence of drug resistance in malaria parasites but facilitates its spread. *PLoS Comput. Biol.* 17 (7), e1008577.
- WHO, World malaria report 2020World Health Organization (2021) <https://www.who.int/publications-detail-redirect/978924001579>.
- World Health Organization, W., Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance, 2010–2019.